Carmen Rodriguez Cueto

Assistant Professor

Universidad Complutense de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Carmen Rodriguez Cueto is an Assistant Professor at Complutense University of Madrid, Spain. Her research focuses on neuroprotective therapies for neurological diseases, particularly in the context of amyotrophic lateral sclerosis and frontotemporal dementia. Recent articles examine the roles of cannabinoid receptors and endocannabinoid elements in mitigating disease progression and neurodegeneration.

Articles (9)

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

María Gómez Cañas

Profesora Ayudante Doctor

Universidad Complutense de Madrid Facultad de Medicina

SPAIN

View details

Jose Lanciego

Staff Scientist & Associate Professor

SPAIN

View details

Javier Fernández-Ruiz

Universidad Complutense de Madrid

SPAIN

View details

ONINTZA SAGREDO EZQUIOGA

Profesora Titular

Universidad Complutense de Madrid

SPAIN

View details

EVA DE LAGO

Profesor Titular

Universidad Complutense de Madrid

SPAIN

View details

Manuel Guzmán

Universidad Complutense de Madrid

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carmen Rodriguez Cueto

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

Editorial: Cannabinoids as potential treatment for neurological diseases

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

Inactivation of the CB 2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

Targeting the CB 2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

Collaborators (6)

María Gómez Cañas

Jose Lanciego

Javier Fernández-Ruiz

ONINTZA SAGREDO EZQUIOGA

EVA DE LAGO

Manuel Guzmán

Make your next move.

Carmen Rodriguez Cueto

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

Editorial: Cannabinoids as potential treatment for neurological diseases

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson&rsquo;s Disease and Amyotrophic Lateral Sclerosis

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

Inactivation of the CB 2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

Targeting the CB 2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

Collaborators (6)

María Gómez Cañas

Jose Lanciego

Javier Fernández-Ruiz

ONINTZA SAGREDO EZQUIOGA

EVA DE LAGO

Manuel Guzmán

Make your next move.

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis